Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080051 · ClinicalTrials.gov registry record · Early Phase 1
Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain
A Early Phase 1 study, sponsored by Molecular NeuroImaging.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 6
- Enrollment target
NCT03080051: Completed Early Phase 1 study, sponsored by Molecular NeuroImaging.
NCT03080051 is a Early Phase 1 study that has completed, run by Molecular NeuroImaging. The registered enrollment target is 6 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03080051, a Early Phase 1 study, has completed, sponsored by Molecular NeuroImaging.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.
Primary Outcome
Descriptive statistics will be applied to describe the tau deposition by region as measured by \[18F\]MNI-952.
Interventions
- DRUG [18F]Florbetapir
- DRUG [18F]MNI-952
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-08 |
| Est. Completion | 2017-03-06 |
| Phase | Early Phase 1 |
What the finished NCT03080051 record still lists
NCT03080051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 2 interventions - of which [18F]Florbetapir is the first listed.
NCT03080051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03080051 about?
NCT03080051 is a clinical study titled "Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain". The overall goal of this imaging trial is to evaluate \[18F\]MNI-952 (also known as \[18F\]UCB-K), a tau targeted PET radioligand.
What is the current status of trial NCT03080051?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 6 participants. The study started on 2016-08. Estimated completion is 2017-03-06.
What interventions are being tested in trial NCT03080051?
The interventions under investigation include: [18F]Florbetapir (DRUG), [18F]MNI-952 (DRUG).
Who is sponsoring clinical trial NCT03080051?
This trial is sponsored by Molecular NeuroImaging, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03080051's enrollment target sits among peer trials
6 1846th of 2000 higher than 114 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia